Pfizer said Sunday that it was buying the rights to a somewhat controversial cell therapy from Athersys, a biotechnology company — a sign of big pharmaceutical companies’ growing interest in stem cells.
Pfizer will have the rights to develop Athersys’s cells to treat inflammatory bowel disease, the companies are expected to announce on Monday. It will pay Athersys $6 million initially and up to $105 million in the future.
read more: http://www.nytimes.com/2009/12/21/business/21pfizer.html
Maybe you can find something interesting in the following sponsored links:
1 Responses to “Pfizer Acquires a Stem-Cell Therapy”
Leave a Reply